109 related articles for article (PubMed ID: 20863716)
1. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
[TBL] [Abstract][Full Text] [Related]
2. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
3. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
4. TSE clearance during plasma products separation process by Gradiflow(TM).
Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
[TBL] [Abstract][Full Text] [Related]
5. Partitioning of TSE infectivity during ethanol fractionation of human plasma.
Gregori L; Maring JA; MacAuley C; Dunston B; Rentsch M; Kempf C; Rohwer RG
Biologicals; 2004 Mar; 32(1):1-10. PubMed ID: 15026020
[TBL] [Abstract][Full Text] [Related]
6. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
Kozak RW; Golker CF; Stadler P
Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
[TBL] [Abstract][Full Text] [Related]
7. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
8. Prion removal by nanofiltration under different experimental conditions.
Yunoki M; Tanaka H; Urayama T; Hattori S; Ohtani M; Ohkubo Y; Kawabata Y; Miyatake Y; Nanjo A; Iwao E; Morita M; Wilson E; MacLean C; Ikuta K
Biologicals; 2008 Jan; 36(1):27-36. PubMed ID: 17890100
[TBL] [Abstract][Full Text] [Related]
9. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.
Neisser-Svae A; Bailey A; Gregori L; Heger A; Jordan S; Behizad M; Reichl H; Römisch J; Svae TE
Vox Sang; 2009 Oct; 97(3):226-33. PubMed ID: 19548963
[TBL] [Abstract][Full Text] [Related]
10. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins.
Gregori L; Gurgel PV; Lathrop JT; Edwardson P; Lambert BC; Carbonell RG; Burton SJ; Hammond DJ; Rohwer RG
Lancet; 2006 Dec; 368(9554):2226-30. PubMed ID: 17189034
[TBL] [Abstract][Full Text] [Related]
11. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
[TBL] [Abstract][Full Text] [Related]
12. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
13. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.
Sowemimo-Coker S; Kascsak R; Kim A; Andrade F; Pesci S; Kascsak R; Meeker C; Carp R; Brown P
Transfusion; 2005 Dec; 45(12):1839-44. PubMed ID: 16371036
[TBL] [Abstract][Full Text] [Related]
14. [Biology of non-conventional transmissible agents or prions].
Dormont D
Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
[TBL] [Abstract][Full Text] [Related]
15. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands.
Gregori L; Lambert BC; Gurgel PV; Gheorghiu L; Edwardson P; Lathrop JT; Macauley C; Carbonell RG; Burton SJ; Hammond D; Rohwer RG
Transfusion; 2006 Jul; 46(7):1152-61. PubMed ID: 16836562
[TBL] [Abstract][Full Text] [Related]
16. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
17. In vitro infectivity assay for prion titration for application to the evaluation of the prion removal capacity of biological products manufacturing processes.
You B; Aubin JT; Le-Hir G; Arzel A; Laude H; Flan B
J Virol Methods; 2010 Mar; 164(1-2):1-6. PubMed ID: 19854223
[TBL] [Abstract][Full Text] [Related]
18. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease.
Herzog C; Rivière J; Lescoutra-Etchegaray N; Charbonnier A; Leblanc V; Salès N; Deslys JP; Lasmézas CI
J Virol; 2005 Nov; 79(22):14339-45. PubMed ID: 16254368
[TBL] [Abstract][Full Text] [Related]
19. Removal of TSE agent from plasma products manufactured in the United Kingdom.
Roberts PL; Dalton J; Evans D; Harrison P; Li Z; Ternouth K; Thirunavukkarasu V; Bulmer M; Fernando S; McLeod N
Vox Sang; 2013 May; 104(4):299-308. PubMed ID: 23170907
[TBL] [Abstract][Full Text] [Related]
20. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.
Lee DC; Stenland CJ; Miller JL; Cai K; Ford EK; Gilligan KJ; Hartwell RC; Terry JC; Rubenstein R; Fournel M; Petteway SR
Transfusion; 2001 Apr; 41(4):449-55. PubMed ID: 11316893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
